Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Incorporate Idera’s TLR Agonists Into Vaccine Program

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck will pay Idera $20 million up front as part of deal.

You may also be interested in...



Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists

Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.

Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists

Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.

Pfizer Halts Lung Cancer Trials Of Toll-Like Receptor Agent

Fate of other oncology trials of the TLR9 candidate Pfizer licensed from Coley has not been made public.

Related Content

Topics

UsernamePublicRestriction

Register

PS063516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel